Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Marketers of cosmetic lash enhancers that haven’t abandoned prostaglandin analogs in favor of peptides or botanical extracts should take heed of a proposed class action against Rodan + Fields in California’s Northern District. Plaintiffs say they would not have purchased the firm’s Lash Boost and suffered alleged adverse effects if they’d been properly informed about product risks.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes

A putative class action targeting Rodan + Fields, LLC in California federal court could draw fresh attention to the use of prostaglandin analogs in cosmetic eyelash enhancers, an issue that has sparked FDA enforcement action in the past, as well as unfair competition suits from Latisse owner Allergan plc.

Filed April 13 in California’s Northern District, Oakland Division, the suit is based on the premise that “disclosing the true...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Archive

Non-US Approvals - Clone

Devices authorized for marketing outside the US. Data derived from Citeline’s Meddevicetracker. Updated weekly.

Patient access to unapproved medical products allowed under DeFazio, Daschle bills.

 
• By 

PATIENT ACCESS TO UNAPPROVED MEDICAL PRODUCTS WOULD BE ALLOWED under legislation introduced by Rep. Peter DeFazio (D-Ore.) on July 12 and Sen. Tom Daschle (D-S.D.) on July 14. Called the Access to Medical Treatment Act, the legislation would allow health practitioners to administer unapproved drugs, devices, foods or dietary supplements to patients as long as there is no evidence the treatment causes harm and the patient is informed about the treatment and its possible side effects. DeFazio's bill is identified as HR 2019; Daschle's version will be assigned a bill number the week of July 17.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

More from HBW Insight

data

Type:DataArticle | Publication:HBW | Section:Health | Paywall:Premium — Article containing all Composer content for testing (Do not update)

 
• By 

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.

Test: PDF Link Lifetime

Description description

headline test

description